WEC
BMY.RT

Winslow Evans & Crocker’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Winslow Evans & Crocker’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		$5K Buy
7,164
+568
+9% +$1.21K ﹤0.01% 1117
2020
Q3 		$15K Hold
6,596
– – ﹤0.01% 677
2020
Q2 		$24K Hold
6,596
– – 0.01% 581
2020
Q1 		$26K Sell
6,596
-410
-6% -$1.35K 0.01% 541
2019
Q4 		$22K Buy
+7,006
New +$18.2K 0.01% 655

Other funds holding BMY.RT

PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BFS
Bard Financial Services Branford, Connecticut $911M AUM 19.14% 1-Year Est. Return
LGP
Leonard Green & Partners Los Angeles, California $2.77B AUM 3.28% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Winslow Evans & Crocker's BMY.RT Position: Q4 2020 in Review

Winslow Evans & Crocker increased its Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) stake by 8.6% in Q4 2020, buying an estimated $1.21K and bringing the position to 7,164 shares worth $5K. The position accounts for ﹤0.01% of the portfolio, ranked #1117.

Winslow Evans & Crocker first reported a position in BMY.RT in Q4 2019 and has held it in 5 quarters since. The position peaked at $26K in Q1 2020. 546 funds tracked by Wall St. Rank hold BMY.RT as of Q4 2020.

  • Winslow Evans & Crocker held 7,164 shares of Bristol-Myers Squibb Company Contingent Value Rights worth $5K as of Q4 2020.
  • Winslow Evans & Crocker bought 568 Bristol-Myers Squibb Company Contingent Value Rights shares in Q4 2020, an estimated $1.21K.
  • Bristol-Myers Squibb Company Contingent Value Rights made up ﹤0.01% of Winslow Evans & Crocker's portfolio in Q4 2020, its #1117 holding.
  • Winslow Evans & Crocker first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and has held it in 5 quarters since.
  • Winslow Evans & Crocker's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $26K in Q1 2020.
  • 546 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q4 2020.

Based on Winslow Evans & Crocker's 13F filing for Q4 2020, filed 3 Feb 2021.